Expression of the mitotic-arrest deficiency 2 is associated with chemotherapy             resistance in ovarian serous adenocarcinoma.
Mitotic-arrest deficiency 2 (MAD2) is a key component of spindle assembly             checkpoint (SAC) function; SAC mediates spindle microtubule attachment to kinetochores             on chromosomes and chromosomal segregation during mitosis. To determine whether             MAD2 expression is associated with chemotherapy resistance in ovarian serous adenocarcinoma,             we reviewed tumor samples from 41 cases of ovarian serous adenocarcinoma at Osaka             City University Medical School Hospital (Osaka, Japan), 2000-2007. Of the 41 cases,             24 were recurrent and 17 were not recurrent. Expression of MAD2 was investigated             in paraffin-embedded sections using a MAD2 antibody. Quantitative analysis of             MAD2 expression gave mean weighted scores of 4.3 for the relapsed group and 7.2             for the relapse-free group; the expression was, thus, significantly greater in             the relapse-free group compared to the relapsed group (P=0.023). When the 41 cases             were classified into low- and high-expression, these classifications showed no             significant difference in terms of progression-free survival (P=0.0685), however,             overall survival for the low-expression group was significantly shorter than that             of the high-expression group (P=0.0188). The present study implies that MAD2 expression             levels can indicate sensitivity to anticancer agents, and risk for recurrence.
Department of Obstetrics and Gynecology, Osaka City University                     Graduate School of Medicine, Osaka 545-8585, Japan.
Yusuke
Y
Nakano
Toshiyuki
T
Sumi
Masatomo
M
Teramae
Masanari
M
Morishita
Takeshi
T
Fukuda
Hiroyuki
H
Terada
Hiroyuki
H
Yoshida
Yoshinari
Y
Matsumoto
Tomoyo
T
Yasui
Osamu
O
Ishiko
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D044466:Asian People / Q000235:genetics; D002135:Calcium-Binding Proteins / Q000378:metabolism*; D018797:Cell Cycle Proteins / Q000378:metabolism*; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy* / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D064246:Mad2 Proteins; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000235:genetics; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D012097:Repressor Proteins / Q000378:metabolism*
D002135:Calcium-Binding Proteins; D018797:Cell Cycle Proteins; C577697:MAD2L1 protein, human; D064246:Mad2 Proteins; D012097:Repressor Proteins